Oct 5 2009, 11:30 AM EST
GEN News Highlights
Seattle Genetics has discontinued development of dacetuzumab for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The firm believes that the mid-stage trial is not likely to meet its primary endpoint of superior complete response rate.
The Phase II MARINER study was a randomized, double-blind investigation of dacetuzumab or placebo in combination with Rituxan® (rituximab) plus ifosfamide, carboplatin, and etoposide (R-ICE) chemotherapy for patients. Initiated in December 2007, the trial was designed to accrue 224 patients, of which approximately two-third were enrolled.
After a planned interim analysis conducted on October 2, the Independent Data Monitoring Committee advised that the trial be closed. The evaluation was conducted on data from approximately half of the 224 total patients.
Dacetuzumab is a humanized mAb that targets the CD40 antigen, which is expressed on most B lineage hematologic malignancies as well as some solid tumors. Seattle Genetics is developing dacetuzumab under a worldwide collaboration agreement with Genentech.
“In collaboration with Genentech, we will conduct a detailed analysis of data from the MARINER trial,” Clay B. Siegall, Ph.D., president and CEO of Seattle Genetics. “In addition, We are continuing four ongoing Phase Ib studies of dacetuzumab for non-Hodgkin’s lymphoma and multiple myeloma.”
♦♦♦
Related News
Millennium Taps Seattle Genetics for Antibody-Drug Conjugate Development with $4M Up Front (Apr. 6, 2009)
Daiichi Sankyo Pays $4M for Access to Seattle Genetics Antibody-Drug Conjugate Platform (July 8, 2008)
Seattle Genetics Earns $4M Milestone Fee from Genentech (Jan. 8, 2008)
Seattle Genetics Achieves $1.5M Milestone in Antibody-Drug Conjugate Deal with MedImmune (Oct. 31, 2007)
Seattle Genetics Enhances Cancer Program with Two Transactions (Jan. 8, 2007)
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More GEN News Highlights
Listen
Save
Comment
View All